Principal Financial Group Inc. Purchases 375,890 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Principal Financial Group Inc. increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 1,058.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 411,414 shares of the biotechnology company's stock after acquiring an additional 375,890 shares during the quarter. Principal Financial Group Inc. owned about 0.20% of BioCryst Pharmaceuticals worth $3,127,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Deerfield Management Company L.P. Series C raised its position in shares of BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company's stock valued at $50,279,000 after acquiring an additional 3,140,804 shares during the last quarter. Kynam Capital Management LP increased its holdings in BioCryst Pharmaceuticals by 41.9% in the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company's stock valued at $33,160,000 after purchasing an additional 1,927,491 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in BioCryst Pharmaceuticals by 528.0% in the second quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company's stock valued at $6,874,000 after buying an additional 935,132 shares during the period. Point72 Europe London LLP bought a new position in BioCryst Pharmaceuticals during the second quarter worth about $1,654,000. Finally, TD Asset Management Inc acquired a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth about $1,487,000. Institutional investors and hedge funds own 85.88% of the company's stock.

Analyst Ratings Changes

BCRX has been the topic of a number of analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Royal Bank of Canada reissued an "outperform" rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. JMP Securities upped their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 6th. StockNews.com upgraded BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, August 6th. Finally, HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $15.60.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX traded up $0.11 on Friday, reaching $7.60. The company had a trading volume of 1,977,442 shares, compared to its average volume of 2,477,516. The company's fifty day moving average is $7.66 and its 200-day moving average is $7.20. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same period in the prior year, the business posted ($0.19) EPS. The firm's quarterly revenue was up 35.1% compared to the same quarter last year. Research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.